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Tom McLellan (Specialty Respiratory Registrar) 
A man in his 30s, with a history of mild childhood asthma only, went to his local 
hospital with difficulty in breathing. His presentation was preceded by six days of 
worsening breathlessness, wheeze and cough. He had been using his mother’s 
salbutamol inhaler and received oral amoxicillin in the community. He was 
hypertensive, tachycardic and had a respiratory rate of 32 breaths per minute. He 
could not complete sentences, peak flow measurement or lie flat. Chest auscultation 
revealed diffuse polyphonic wheeze. Arterial blood gas (ABG) whilst receiving 
fraction of inspired oxygen (FiO2) 40% revealed pH 7.32, PaO2 9.7kPa, PaCO2 
6.7kPa. He had a blood eosinophil count of 0.5 x109/L, serum CRP 30mg/L with 
normal renal and liver profiles. His chest radiograph (figure 1a) revealed clear lung 
fields with no pneumothorax or consolidation. He was treated with nebulised 
bronchodilators, intravenous broad-spectrum antibiotics, magnesium, hydrocortisone 
and aminophylline before transfer to the High Dependency Unit.  
 
Over 48 hours there was an improvement and treatments were gradually weaned but 
on day three there was a respiratory deterioration associated with a PaCO2 of 
7.6kPa requiring intubation. Treatment was augmented with a ketamine infusion and 
inhaled sevoflurane. Despite optimum ventilation strategies, four hours after 
intubation there was severe gas trapping requiring manual decompression, low tidal 
volumes and a rising arterial PaCO2. A referral to the local extracorporeal membrane 




Chinmay Patvardhan (Consultant Intensivist) 
On our arrival, the patient was in ventilatory failure with severe gas trapping. Pre-
ECMO ABG (FiO2 60%) showed pH 6.98, PaO2 10.7kPa, PaC02 17.8kPa. Veno-
venous ECMO was initiated at 4.9 litres per minute (L/min) flow and sweep of 3L/min 
without incident and he was transferred to the ECMO centre. 
 
During the first few days, treatment continued with intravenous hydrocortisone, 
broad-spectrum antibiotics and antivirals. Intravenous salbutamol, ketamine and 
aminophylline were used as bronchodilating agents. A computerised tomography 
(CT) scan was performed on day 1 of ECMO treatment. This showed no 
abnormalities in the abdomen, pelvis, head or neck. ECMO cannulae were 
appropriately placed. There were a few small patchy areas of consolidation and 
ground glass (Figure 1b). There were no features of chronic lung disease. 
  
Bronchoalveolar lavage (BAL) for extended bacterial, fungal and viral cultures, 
including PCR microarray were negative as were serum viral and bacterial screens. 
Broad spectrum antibiotics were continued, oseltamivir was stopped. The patient 
was haemodynamically stable and vasopressor support was stopped 3 days after 
ECMO initiation. Intravenous salbutamol was switched to regular nebulised therapy. 
 
Despite bronchodilation and intravenous steroids, the patient remained obstructed 
requiring an ECMO sweep flow of 7-8L/min to normalise arterial PaCO2. There was 
a persistent blood eosinophil count of 1.0x109/L. He required repeat bronchoscopies 
because of thick secretions. Chest radiographs showed evidence of right lower lobe 
collapse. On day 3 of ECMO therapy hydrocortisone was stopped and the patient 
was pulsed for 3 days with methylprednisolone (0.5-1 gram daily). There was no 
evidence of malabsorption and he was subsequently treated with prednisolone at 
0.5mg/kg daily. His BAL samples were reviewed by the pathology team. 
 
Doris Rassl (Consultant Histopathologist) 
A total of five BAL samples were received for this patient. The first was performed on 
day 1 of ECMO cannulation. The differential cell count was eosinophil rich (35%) 
(figure 1c). BALs performed during and just after treatment with methylprednisolone 
on days 8 and 10 showed evidence of reduced eosinophil counts (3 and 5% 
respectively). There were no haemosiderin laden macrophages or other features 
consistent with haemorrhage on any sample. Immunophenotyping using flow 
cytometry showed evidence of normal B and T cell lymphocyte populations. Cytology 
revealed evidence of branching fungal hyphae.  
 
 Chinmay Patvardhan 
Whilst methylprednisolone supressed the peripheral eosinophil count, the patient’s 
lack of clinical progress caused concern. BAL and serum galactomannan and Beta-D 
Glucan levels were normal but amphotericin B was still commenced.  The eosinophil-
rich BAL raised the possibility of eosinophilic granulomatosis with microscopic 
polyangiitis (EGPA). After discussion with the regional vasculitis service he 
underwent plasma exchange between days 8 and 11 of EMCO therapy. This made 
no difference to his clinical condition. A BAL performed on day 12 of ECMO 
treatment (after plasma exchange) revealed similar features to earlier investigations 
with a rising eosinophil count of 58% (figure 1d). By day 13 the patient remained 
bronchospastic and it was not possible to further reduce ECMO requirements. An 
opinion was sought from the Interstitial Lung Disease team. 
 
Muhunthan Thillai (Consultant ILD Physician) 
The patient was a current smoker with a 5-pack year history who had never vaped, 
had childhood asthma but not required inhaled therapy since aged 18. There was no 
history of peripheral neuropathy, sinus, or skin disease. He took no over the counter 
or prescribed medication and had used non-steroidal treatment and amoxicillin 
without incident. There was no history of foreign travel. As a teenager he played 
football to a semi-professional standard and was now the main carer for his mother. 
Their accommodation was in good condition without obvious fungus or mould 
exposure.  
 
Investigations revealed normal protein electrophoresis with a mildly raised total 
serum IgE of 155kU/L. Aspergillus IgG titres were 17mg/L.  Serology for helminths 
and parasites was normal. Urinalysis, autoimmune and vasculitic screens were 
bland.   
 
A transbronchial or surgical lung biopsy would have been useful but given the 
significant ECMO requirements and risk of bleeding this was not performed. Acute 
idiopathic eosinophilic pneumonia presents with an acute illness and is more 
common in young men who smoke. Peripheral eosinophilia may be present and a 
BAL eosinophil count of >25% is part of the diagnostic criteria. However, whilst some 
patients require mechanical ventilation, this is due to type 1 respiratory failure and 
gas trapping is not a feature. The presenting chest radiograph did not show 
consolidation and whilst there were small patches of ground glass and consolidation 
on CT, these did not account for the severity of illness. The condition usually 
responds rapidly to steroid therapy. No agent causing a drug reaction could be 
identified. The results were not consistent with acute hypersensitivity pneumonitis. A 
negative antineutrophil cytoplasmic antibody does not exclude EGPA but the short 
history and single organ involvement made this diagnosis unlikely. The patient did 
not meet criteria for hypereosinophilic syndrome. A specialist asthma opinion was 
sought.  
 
Martin Knolle (Consultant Asthma Physician) 
The history and results of investigations were reviewed and it was felt an acute 
asthma exacerbation was still the most likely diagnosis. The cause of exacerbation 
was unclear, but young patients may present acutely having had sub-clinical 
symptoms for some time. The presence of fungal hyphae on BAL suggested a 
potential trigger, but on balance was felt more likely to represent airway colonisation 
during ECMO treatment. Conventional therapy had not improved his condition. 
Rescue treatment with mepolizumab was considered and after discussion with the 
patient’s next of kin, 100mg was administered subcutaneously on day 14 of ECMO 
treatment. 
 
 Chinmay Patvardhan 
There was an improvement in the patient’s condition. He was decannulated on day 
16 of ECMO therapy and repatriated, (figure 1c).  
 
Huw Jenkins (Consultant Chest Physician) 
After repatriation the patient completed a largely uneventful 4-week admission. The 
peripheral eosinophil count remained normal and repeat BAL had an eosinophil 
count of 8%. He was discharged on oral prednisolone and a beclomethasone-
formoterol inhaler. Pulmonary function testing at three months revealed FEV1 2.87L 
(73%) FVC 4.07L (86%), TLCO 73% KCO 103%. He has been followed up for 18 
months. Oral steroids have been weaned and there have been no other acute 
exacerbations or medical presentations. Repeat chest radiographs, serum 
aspergillus and immunoglobulin results have been normal. His blood eosinophil 
count has not exceeded 0.4x109/L. His fractional exhaled nitric oxide level is normal.  
 
Discussion 
A high lung eosinophil count has a range of differential diagnoses. In this case the 
obstructive pattern of disease, lack of drug exposure, normal ANCA levels and 
relatively normal lung parenchyma on imaging pointed towards asthma as the most 
likely primary cause. ECMO improves survival in near-fatal asthma when mechanical 
ventilation fails, however a positive response is usually seen within days and the 
mean duration of treatment in survivors is 7 days (1). This patient required a total of 
16 days of ECMO therapy and by day 14 was not showing signs of improvement 
despite maximal conventional therapy. 
 
Mepoluzimab, an anti-interleukin 5 (IL5) monoclonal antibody, is an effective 
treatment in severe, chronic eosinophilic asthma (2,3) but is not approved by NICE in 
the United Kingdom for use in acute exacerbations. The decision to use it was made 
(after discussion with the family) by specialists with experience of acute asthma, anti-
IL5 therapy and ECMO, who completed the appropriate hospital pharmacy 
application for off-licence use and were in agreement that the potential benefits 
outweighed the risks in this specific case. The patient may have improved without 
mepolizumab therapy but the change in clinical condition 48 hours after 
administration was striking. To our knowledge, this is the first recorded instance of it 
being used as rescue therapy in a near-fatal exacerbation. Benraluzimab has a more 
rapid eosinophil depleting action and has been used successfully in an acute 
exacerbation (4). However, our unit did not have experience with benraluzimab at 
the time of use. Mepoluzimab may have a slower time of action but does still begin to 
reduce the peripheral eosinophil count within 24 hours of administration (5). Despite 
patient improvement, we cannot prove a causal relationship with drug administration 
and this, as well as the potential synergistic effect between steroids and anti-IL5 
therapy in an acute exacerbation, warrant further investigation. Patients who present 
with near-fatal asthma require careful long-term assessment in the outpatient clinic 
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